Mitigating Cardiovascular Risk in Obesity


Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

To watch the video series component of this episode, click here.

1:14 Obesity and cardiovascular risk

3:28 Topline findings for semaglutide in the SELECT trial

7:15 CV risk reduction with semaglutide

8:54 Perspectives on cost-benefit for GLP-1 in obesity

14:14 Outcomes from STEP HFpEF trial

16:44 Considerations for using GLP-1 agonists

20:54 Need to address inequity in access to obesity medications

26:44 Investigational therapies for obesity with potential for CV benefits

30:00 Combination therapy for obesity and CV risk

Related Videos
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 5 cardiovascular experts
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
© 2024 MJH Life Sciences

All rights reserved.